SHIRE PLC
SHPGF evidence brief
What we can confirm
- BioSniper Score:
- 8.3 / 10
- Lead Asset:
- elaprase (Approved)
What it means
What to watch
Prepared research question
What matters most for SHPGF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Sep 30, 2018.
Tracking 3 pipeline candidates · 19 clinical trials · 2 FDA decisions for SHIRE PLC.
Run SHIRE PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SHIRE PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.71 · 1% dilution
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is SHIRE PLC's lead drug candidate?
SHIRE PLC's most advanced tracked candidate is elaprase (Approved) for Hunter Syndrome.
What therapeutic areas does SHIRE PLC focus on?
SHIRE PLC develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Dermatology, Hematology, Gastroenterology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.